$8.64
3.46% day before yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US45257U1088
Symbol
IMNM
Sector
Industry

Immunome Inc Target price 2025 - Analyst rating & recommendation

Immunome Inc Classifications & Recommendation:

Buy
93%
Hold
7%

Immunome Inc Price Target

Target Price $23.46
Price $8.64
Potential
Number of Estimates 10
10 Analysts have issued a price target Immunome Inc 2026 . The average Immunome Inc target price is $23.46. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 14 Analysts recommend Immunome Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Immunome Inc stock has an average upside potential 2026 of . Most analysts recommend the Immunome Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 9.04 4.91
35.52% 45.73%
EBITDA Margin -1,680.20% -4,054.22%
733.26% 141.29%
Net Margin -3,240.71% -4,000.45%
325.38% 23.44%

10 Analysts have issued a sales forecast Immunome Inc 2025 . The average Immunome Inc sales estimate is

$4.9m
Unlock
. This is
55.16% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$9.5m 13.62%
Unlock
, the lowest is
$2.8m 74.02%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $9.0m 35.52%
2025
$4.9m 45.73%
Unlock
2026
$17.6m 259.34%
Unlock
2027
$73.4m 316.26%
Unlock
2028
$160m 118.65%
Unlock
2029
$221m 37.71%
Unlock
2030
$377m 70.77%
Unlock
2031
$768m 103.57%
Unlock
2032
$1.1b 47.64%
Unlock

3 Analysts have issued an Immunome Inc EBITDA forecast 2025. The average Immunome Inc EBITDA estimate is

$-199m
Unlock
. This is
13.18% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-205m 16.51%
Unlock
, the lowest is
$-191m 8.75%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-152m 437.28%
2025
$-199m 30.95%
Unlock
2026
$-195m 2.05%
Unlock

EBITDA Margin

2024 -1,680.20% 733.26%
2025
-4,054.22% 141.29%
Unlock
2026
-1,105.11% 72.74%
Unlock

11 Immunome Inc Analysts have issued a net profit forecast 2025. The average Immunome Inc net profit estimate is

$-196m
Unlock
. This is
4.31% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-167m 18.36%
Unlock
, the lowest is
$-222m 8.44%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-293m 174.28%
2025
$-196m 33.01%
Unlock
2026
$-214m 8.94%
Unlock
2027
$-196m 8.55%
Unlock
2028
$-64.2m 67.15%
Unlock
2029
$6.9m 110.70%
Unlock
2030
$131m 1,810.77%
Unlock
2031
$183m 39.19%
Unlock
2032
$317m 73.30%
Unlock

Net Margin

2024 -3,240.71% 325.38%
2025
-4,000.45% 23.44%
Unlock
2026
-1,212.86% 69.68%
Unlock
2027
-266.44% 78.03%
Unlock
2028
-40.02% 84.98%
Unlock
2029
3.11% 107.77%
Unlock
2030
34.79% 1,018.65%
Unlock
2031
23.79% 31.62%
Unlock
2032
27.92% 17.36%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -5.00 -2.26
7.06% 54.80%
P/E negative
EV/Sales 88.56

11 Analysts have issued a Immunome Inc forecast for earnings per share. The average Immunome Inc EPS is

$-2.26
Unlock
. This is
12.40% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.93 25.19%
Unlock
, the lowest is
$-2.56 0.78%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-5.00 7.06%
2025
$-2.26 54.80%
Unlock
2026
$-2.46 8.85%
Unlock
2027
$-2.25 8.54%
Unlock
2028
$-0.74 67.11%
Unlock
2029
$0.08 110.81%
Unlock
2030
$1.51 1,787.50%
Unlock
2031
$2.10 39.07%
Unlock
2032
$3.64 73.33%
Unlock

P/E ratio

Current -3.35 21.93%
2025
-3.83 14.37%
Unlock
2026
-3.51 8.36%
Unlock
2027
-3.84 9.40%
Unlock
2028
-11.70 204.69%
Unlock
2029
109.30 1,034.19%
Unlock
2030
5.72 94.77%
Unlock
2031
4.11 28.15%
Unlock
2032
2.37 42.34%
Unlock

Based on analysts' sales estimates for 2025, the Immunome Inc stock is valued at an EV/Sales of

88.56
Unlock
and an P/S ratio of
153.24
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 39.71 3.29%
2025
88.56 123.01%
Unlock
2026
24.65 72.17%
Unlock
2027
5.92 75.98%
Unlock
2028
2.71 54.26%
Unlock
2029
1.97 27.38%
Unlock
2030
1.15 41.44%
Unlock
2031
0.57 50.88%
Unlock
2032
0.38 32.27%
Unlock

P/S ratio

Current 68.72 2.78%
2025
153.24 122.99%
Unlock
2026
42.65 72.17%
Unlock
2027
10.24 75.98%
Unlock
2028
4.69 54.26%
Unlock
2029
3.40 27.38%
Unlock
2030
1.99 41.44%
Unlock
2031
0.98 50.87%
Unlock
2032
0.66 32.26%
Unlock

Current Immunome Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Lake Street
Locked
Locked
Locked Apr 02 2025
Guggenheim
Locked
Locked
Locked Mar 20 2025
Stephens & Co.
Locked
Locked
Locked Mar 20 2025
Wedbush
Locked
Locked
Locked Mar 20 2025
LifeSci Capital
Locked
Locked
Locked Mar 11 2025
Piper Sandler
Locked
Locked
Locked Nov 14 2024
Stephens & Co.
Locked
Locked
Locked Nov 08 2024
Analyst Rating Date
Locked
Lake Street:
Locked
Locked
Apr 02 2025
Locked
Guggenheim:
Locked
Locked
Mar 20 2025
Locked
Stephens & Co.:
Locked
Locked
Mar 20 2025
Locked
Wedbush:
Locked
Locked
Mar 20 2025
Locked
LifeSci Capital:
Locked
Locked
Mar 11 2025
Locked
Piper Sandler:
Locked
Locked
Nov 14 2024
Locked
Stephens & Co.:
Locked
Locked
Nov 08 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today